Oct 2, 2026 06:04AM
Oct 2, 2026 02:30AM
Sep 29, 2026 12:12PM
Sep 28, 2026 05:33PM
Sep 28, 2026 05:30PM
Sep 25, 2026 07:01AM
Sep 25, 2026 07:00AM Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
Sep 25, 2026 06:02AM
Sep 18, 2026 06:09AM
Sep 8, 2026 07:50AM
Sep 8, 2026 07:50AM
May 27, 2026 04:04AM
Mar 9, 2026 08:45AM
Mar 9, 2026 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
Mar 9, 2026 02:30AM
Feb 3, 2026 07:00AM
Feb 3, 2026 07:00AM
Feb 3, 2026 04:11AM
Feb 3, 2026 02:30AM
Dec 2, 2025 09:18AM
Dec 2, 2025 09:18AM Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
Oct 1, 2025 07:00AM
Oct 1, 2025 07:00AM
Sep 24, 2025 07:00AM
Sep 24, 2025 02:30AM
Jul 28, 2025 07:01AM
Jul 28, 2025 07:00AM
Jan 13, 2025 07:00AM Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
Jan 13, 2025 06:09AM
Jan 13, 2025 02:00AM
Dec 11, 2024 09:44AM
Dec 6, 2024 07:00AM
Dec 6, 2024 06:14AM
Oct 3, 2024 07:04AM
Oct 3, 2024 07:00AM CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
Oct 3, 2024 06:11AM
Oct 1, 2024 07:06AM
Oct 1, 2024 07:00AM
Oct 1, 2024 06:19AM
Oct 1, 2024 02:00AM
Sep 13, 2024 04:00AM
Aug 15, 2024 07:02AM AstraZeneca’s (AZN) IMFINZI Granted FDA Priority Review and Breakthrough Therapy Designation
Aug 15, 2024 07:00AM
Jun 10, 2024 07:00AM
Jun 10, 2024 06:03AM
Jun 10, 2024 04:36AM
Apr 2, 2024 07:00AM
Apr 2, 2024 05:36AM
Apr 2, 2024 02:00AM Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Feb 19, 2024 07:10AM

15,862 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All